NASDAQ:MXCT - Nasdaq - US57777K1060 - Common Stock - Currency: USD
NASDAQ:MXCT (5/9/2025, 10:15:07 AM)
2.3417
-0.09 (-3.63%)
The current stock price of MXCT is 2.3417 USD. In the past month the price decreased by -3.95%. In the past year, price decreased by -48.73%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 18.63 | 154.03B | ||
DHR | DANAHER CORP | 25.91 | 138.12B | ||
A | AGILENT TECHNOLOGIES INC | 20.25 | 30.66B | ||
IQV | IQVIA HOLDINGS INC | 13.55 | 26.99B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 27.21 | 22.94B | ||
WAT | WATERS CORP | 29.26 | 20.73B | ||
WST | WEST PHARMACEUTICAL SERVICES | 32.22 | 15.37B | ||
ILMN | ILLUMINA INC | 22.77 | 12.00B | ||
ICLR | ICON PLC | 10.06 | 11.40B | ||
RVTY | REVVITY INC | 18.67 | 11.06B | ||
TEM | TEMPUS AI INC | N/A | 11.02B | ||
QGEN | QIAGEN N.V. | 18.54 | 9.22B |
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Rockville, Maryland and currently employs 114 full-time employees. The company went IPO on 2016-03-29. The company leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. The company also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
MAXCYTE INC
9713 Key West Avenue,, Suite 400
Rockville MARYLAND US
CEO: Doug Doerfler
Employees: 114
Phone: 13015175556
The current stock price of MXCT is 2.3417 USD. The price decreased by -3.63% in the last trading session.
The exchange symbol of MAXCYTE INC is MXCT and it is listed on the Nasdaq exchange.
MXCT stock is listed on the Nasdaq exchange.
11 analysts have analysed MXCT and the average price target is 7.48 USD. This implies a price increase of 219.42% is expected in the next year compared to the current price of 2.3417. Check the MAXCYTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MAXCYTE INC (MXCT) has a market capitalization of 248.95M USD. This makes MXCT a Micro Cap stock.
MAXCYTE INC (MXCT) currently has 114 employees.
MAXCYTE INC (MXCT) has a resistance level at 4.81. Check the full technical report for a detailed analysis of MXCT support and resistance levels.
The Revenue of MAXCYTE INC (MXCT) is expected to grow by 9.03% in the next year. Check the estimates tab for more information on the MXCT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MXCT does not pay a dividend.
MAXCYTE INC (MXCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
The outstanding short interest for MAXCYTE INC (MXCT) is 3.5% of its float. Check the ownership tab for more information on the MXCT short interest.
ChartMill assigns a fundamental rating of 4 / 10 to MXCT. MXCT has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months MXCT reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS decreased by -14.29% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -17.14% | ||
ROE | -19.91% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 87% to MXCT. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 6.89% and a revenue growth 9.03% for MXCT